Evidence Hub

Rheumatic Immune-Related Adverse Events With Anti-cyclic Citrullinated Peptide Positivity and Cutaneous Adverse Drug Reactions: A Case Report

Yamazaki A, Nakano E, Yoshida T

Cureus, 2024

Abstract

We report the case of a patient who experienced rheumatic immune-related adverse events (irAEs) with anti-cyclic citrullinated peptide (anti-CCP) positivity and cutaneous adverse drug reactions. A 59-year-old woman with malignant melanoma who was treated with nivolumab as postoperative adjuvant therapy developed polyarthralgia with anti-CCP positivity and dermatologic adverse events caused by celecoxib or lansoprazole. Her rheumatic and cutaneous symptoms greatly improved with oral glucocorticoid treatment. The findings of this case suggest that after treatment with immune checkpoint inhibitors, it is necessary to pay attention to irAEs and provide appropriate treatment.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free